JPH01242531A - Glucose electrolyte blend - Google Patents

Abstract

PURPOSE:To obtain a blend, having high safety even for a patient suffering from hepatopathy and hemorrhagic shock without causing precipitation of calcium phosphate, etc., even in treatment at high temperatures in sterilization, by adjusting a blend containing glucose and an electrolyte to a specific pH with acetic acid. CONSTITUTION:A blend prepared by dissolving glucose, ZnSO4.7H2O, MgSO4.7 H2O, K2HPO4, NaCl, CH3COONa.3H2O, CH3COOK and calcium gluconate- hydrate in distilled water for injection is adjusted to pH 4.0-5.0 with acetic acid. The respective component composition in 1l above-mentioned blend is 200-300g glucose, 30-60mmol sodium, 20-60mmol potassium, 5-10mmol calcium, magnesium and phosphorus, 5-12micromol zinc and 5-15mmol chlorine. The afore-mentioned agent is especially suitable in mixed use with other nutrients, such as amino acid transfusion solution, in administration through veins to patients incapable of oral administration.

Description

[Detailed Description of the Invention] [Industrial Application Field] The present invention provides a glucose-electrolyte combination preparation, which can be mixed with other nutrients such as amino acid infusions, especially when administered intravenously to patients who are unable to administer oral administration. The present invention relates to a glucose electrolyte formulation suitable for use.

[Conventional technology]

In order for a living organism to maintain its life, it is essential to ingest not only the three major nutrients of carbohydrates (sugars, starches, etc.), proteins (amino acids), and fats, but also the five major nutrients including various inorganic substances and vitamins. ing.

Therefore, when it is impossible to ingest these nutrients orally for some reason, intravenous administration using infusion preparations containing these nutrients is widely practiced.

A single infusion preparation containing all the nutrients that satisfies this nutritional administration method does not yet exist due to the lack of stability among the ingredients, such as the formation of precipitates and discoloration due to the Maillard reaction.

For this reason, currently, several infusion preparations are prepared in two parts and mixed together in a combination suitable for the patient before administration, and administered as a complete zero-pulse administration preparation. In both formulations, the base solution is a compound containing glucose and electrolytes, to which are added other amino acids, fat emulsions, and other infusion fluids required during administration.

The above-mentioned compound containing the base liquid glucose and electrolyte contains phosphorus and calcium in its components, but these components can be mixed and contained using substances such as potassium phosphate and calcium gluconate. When heat sterilized, calcium phosphate precipitates are formed, so it cannot be used as a basic solution for infusion. Furthermore, if glucose is contained, this formulation has the disadvantage of being colored when it is heat sterilized. For this reason, the pH is adjusted to 4.0 to 5.0 + by adding acid, and it is known that the above-mentioned precipitation and discoloration of calcium phosphate do not occur within this pH range.

Therefore, it is necessary to adjust the pH to 4.0 to 5.0 by adding an acid to the grape electrolyte formulation.Acids that can be used for this purpose include inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, and lactic acid. However, when adjusting pH using these medium inorganic acids, acidosis due to these inorganic acids may occur because salts of these acids are contained in the various electrolytes that should be included in the compounding agent. Therefore, organic acids are used for pH adjustment in current grape electrolyte formulations.

[Problem to be solved by the invention]

However, since lactic acid is metabolized in the liver, it is known that in patients with severe liver disease or in hemorrhagic shock, lactic acid metabolism in the liver decreases, resulting in lactic acidosis. It is undesirable to use a stagnant electrolyte formulation.

Therefore, the object of the present invention is to provide a grape electrolyte that is highly safe for use in patients with liver disease or patients undergoing hemorrhagic shock, and which does not cause calcium phosphate precipitation or discoloration even when subjected to high temperature treatment such as during sterilization. The objective is to provide combination drugs.

[Means to solve the problem]

The present invention is a combination product containing grapes and an electrolyte, the pH of which is adjusted to 4.0 to 50 with acetic acid.

Among the electrolytes that can be used in the present invention, n) sodium chloride, sodium acetate, etc. as an IJium source, potassium acetate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, etc. as a potassium source, magnesium sulfate, etc. as a magnesium source; , calcium acetate, calcium gluconate, etc. as a calcium source, sodium chloride, etc. as a chloride source,
Dipotassium hydrogen phosphate, potassium dihydrogen phosphate, etc. can be used as a colorant, and zinc sulfate, etc. can be used as a zinc source. These are well known to those skilled in the art.

Preferred glucose electrolysis T1 formulations are shown below.

The following components are 11AR in aqueous solution 11.

Glucose 200-300 & Sodium 30-60 mmol Potassium
20-60 mmol calcium
5-10 mm red sea bream sea bream
5-10 mmol fl)
5-12 micromol chlor 5
~15 mmol phosphorus 5-10
Millimoles According to the present invention, the pH of the above-mentioned glucose electrolysis negative compound (aqueous solution) is adjusted to 4.0 to 5.0G with acetic acid.

[For production]

In the grape electrolyte formulation according to the present invention, its p
Since H is adjusted to 4.0 to 5.0 with acetic acid, it is stable and does not produce precipitates even after heat sterilization, and does not change color. Moreover, acetic acid is not metabolized only by specific metabolic organs, especially the liver. Since it is efficiently utilized by the muscles, it is metabolized outside the liver even when administered to patients with liver disease or in shock, and its metabolic rate is very fast, and it is completely metabolized to water and carbon dioxide.

〔Example〕

The present invention will be explained below with reference to Examples.

Example 1 112.59 glucose, 1.3 +I19 ZnSO
4”7HmO16161n9 Mg5O, -7) 1.0
．． 6271! )IPO,,175η of NaC1,
2235151 CHsCOONae3H*01125
Dissolve 10651Q of calcium gluconate hydrate in 6 m9 of CH, COO and 300 m of distilled water for injection, add acetic acid to adjust the pH to 4.5, and then add distilled water for injection to dissolve the whole. 400-. This was placed in a glass vial (700d) and sterilized by heating according to the diurnal sterilization method. This product did not change color and did not form any precipitate.

The composition of each component in the above formulation 11 is shown below.

Glucose 281.3 g Sodium 48.6 mmol Potassium
41 mmol calcium
5.9 mmol mag base sium
6.3 mmol zinc 11.
3 micromol chlor 7.5
mmol Phosphorus 9 mmol Example 2 120 p O) Dextrose, 1.3 "9 (') Z
n5O-”7H electric 0゜616 ny tgsoa”7
To 1627 Ing of HsO, add HPO, 175 ml (1
) NaC1,2235rnt)ノCH, COONa・
3H, 0°1256■C)1. cOO and 466
Dissolve W/'s (CH*C00)*Ca ・2H-0 in 250ml of distilled water for injection, and add acetic acid to adjust the pH to 4.5.
Add distilled water for injection to bring the total volume to 400μ.
And so. The following treatment was carried out in the same manner as in Example 1. This product did not change color and did not form any precipitate.

The composition of each component in the above compounding agent 1 is shown below.

Glucose 3001 Sodium 48.6 mmol Potassium 41 mmol Calcium 6 mmol Magnesium
6.3 mmol zinc
11.3 micromol chlor
7.5 mmol phosphorus
9 mmol Example 3 80g glucose, 0.72q Zn5Oi”7H*0
.

616■ Mg5Oa '71 (,0,501■,
) IPO,, 175■ NaCノ, 2235# CHm
COONa e 3Hm 0゜1006 ~ CH,C
00K and 466 ~ (CHs C00)-Ca・2
H-0 was dissolved in 25ON of distilled water for injection, and acetic acid was added to adjust the pH to 4.5, followed by addition of distilled water for injection to make the total pH 400. The following treatment was carried out in the same manner as in Example 1. This product did not change color and no precipitate was formed.

The above compounding agent 1! The composition of each component inside is 200. p Sodium 48.6 mmol Potassium
32,8 “Calcium
6 “Magnesium
6.3 “Zinc 6.3
Micromolcro/L7 7
．． 5 mmol phosphorus 7.2
"[Effects of the Invention] The phlegm electrolyte combination according to the present invention uses acetic acid to adjust the pH WA, so even when administered to patients with liver disease, it is metabolized and has excellent effects without causing precipitation or discoloration.

Claims (1)

[Claims] 1. In a combination drug containing glucose and electrolytes,
A glucose electrolyte formulation whose pH is adjusted to 4.0 to 5.0 with acetic acid. 2. The following ingredients in an aqueous solution Glucose 200-300 g/l Sodium 30-60 mmol/l Potassium 20-60 mmol/l Calcium 5-10 mmol/l Magnesium 5-10 mmol/l Zinc 5-12 micromol/l Chlor The glucose electrolyte formulation according to claim 1, containing 5 to 15 mmol/l of phosphorus and 5 to 10 mmol/l of phosphorus.